Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(o)(4)) authorizes FDA to require application holders for certain drugs to make labeling changes based on new safety information. Learn more.
Similar Posts
Angiographic Catheter Recall: Cook Removes Beacon Tip Angiographic Catheters due to Tip Separation
Affected device lots may experience tip separation; field complaints reported that the tip separation can occur both prior to and during patient contact.Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential product carton strength mislabeling.Concord Biotech Limited – 04/28/2025-05/02/2025
Concord Biotech Limited – 04/28/2025-05/02/2025. Country: India. Record Type: 483Walgreen Company – 662158 – 12/19/2025
Failure to Register and Listwww.buycodeine.us – 702527 – 05/05/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetNature’s Fusions LLC – 707024 – 06/25/2025
CGMP/Finished Pharmaceuticals/Adulterated